Gilead Sciences (GILD) – Reuters
-
Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
-
Gilead quarterly revenue drops 4%, oral COVID drug fails trial
-
Gilead quarterly results beat Street estimates as lower taxes boost profit
-
Gilead profit misses Wall Street expectations as COVID drug sales decline
-
Gilead profit beats Street expectations on COVID and HIV sales
-
Gilead, Kite in process of pausing Twitter advertising
-
Gilead quarterly profit falls as COVID antiviral sales decrease
-
EU signs COVID-19 drug procurement deal with Gilead
-
Gilead's remdesivir fails to show benefit in European trial; no fetus risk seen with first trimester vaccination
-
GSK to get $1.25 billion to settle HIV drug patent row with Gilead
-
Gilead earnings hurt by legal settlement, other charges
-
Gilead trims 2021 sales forecast for non-COVID products
-
Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers
-
Wall Street closes lower as surging COVID-19 cases offset vaccine hopes
-
Don't use Gilead's remdesivir in hospitalised COVID-19 patients, WHO says
-
Gilead cuts 2020 sales outlook as COVID-19 drug remdesivir falls short
-
Wall Street closes higher, trade choppy as U.S. stimulus talks eyed
-
Remdesivir questioned by WHO trial; women take virus more seriously than men
-
U.S. pauses Eli Lilly trial of antibody drug Trump touted as COVID-19 'cure' over safety concern
-
HHS says Gilead, distributor can directly sell COVID-19 drug in U.S.
-
Tech, healthcare mega deals boost virus-stricken M&A market
-
Gilead's shares rise after $21 billion deal for Immunomedics
-
Exclusive: U.S. hospitals turn down remdesivir, limit use to sickest COVID-19 patients
-
Gilead: FDA could expand remdesivir use despite mixed data
-
Gilead shares slide after FDA knocks back rheumatoid arthritis drug
-
Gilead seeks U.S. approval for COVID-19 treatment remdesivir
-
Pfizer to make Gilead's COVID-19 treatment remdesivir
-
Merck to move COVID-19 treatment into large trials, sees sales recovering this year
-
EU buys remdesivir to treat 30,000 COVID patients, seeks more
-
Gilead analysis shows remdesivir reduced coronavirus death risk, more studies needed
-
Wall Street jumps with financials; Gilead data offsets virus fears
-
U.S. dollar slides as vaccine news offsets surge in virus cases
-
Gilead to deliver more remdesivir to Europe from autumn: WiWo
-
Exclusive: EU secures potential COVID-19 drugs from Roche, Germany's Merck
-
GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
-
Wall Street ends higher on Boeing bump, stimulus eyed
-
Gilead targets remdesivir supply for two million COVID-19 patients by year-end
-
U.S. hospitals in hard hit regions step up use of steroids on sickest COVID-19 patients
-
Steroid drug hailed as 'breakthrough' for seriously ill COVID-19 patients
-
AstraZeneca contacted Gilead over potential megamerger: Bloomberg News
-
Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst
-
Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions
-
Gilead's remdesivir shows modest improvement in moderate COVID-19 patients
-
Wall Street closes higher as recovery signs soothe protest, pandemic worries
-
Gilead trades that made millions on COVID-19 drug news raise eyebrows
-
Gilead study shows shorter five-day course of remdesivir works as well as 10-day one
-
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
-
U.S. doctors call for remdesivir data to guide coronavirus treatment
-
Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources
-
Will Gilead price its coronavirus drug for public good or company profit?
Back to GILD Stock Lookup
